Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.
Thromb Haemost. 2019 May;119(5):834-843. doi: 10.1055/s-0039-1678737. Epub 2019 Feb 19.
The kallikrein/kinin system, an intravascular biochemical pathway that includes several proteins involved in the contact activation system of coagulation, renin-angiotensin activation and inflammation, may or may not play a role in venous thromboembolism (VTE) occurrence. Within a large prospective population-based study in the United States, we conducted a nested case-cohort study to test the hypothesis that higher plasma levels of high molecular weight kininogen (HK) or prekallikrein are associated with greater VTE incidence. We related baseline enzyme-linked immunosorbent assay measures of HK and prekallikrein in 1993 to 1995 to incidence VTE of the lower extremity ( = 612) through 2015 (mean follow-up = 18 years). We found no evidence that plasma HK or prekallikrein was associated positively with incident VTE. HK, in fact, was associated inversely and significantly with VTE in most proportional hazards regression models. For example, the hazard ratio of VTE per standard deviation higher HK concentration was 0.88 (95% confidence interval = 0.81, 0.97), after adjustment for several VTE risk factors. Our findings suggest that plasma levels of these factors do not determine the risk of VTE in the general population.
激肽释放酶/激肽系统是一种血管内生化途径,其中包括几种参与凝血接触激活系统、肾素-血管紧张素激活和炎症的蛋白质,它可能在静脉血栓栓塞症(VTE)的发生中发挥作用,也可能没有发挥作用。在美国一项大型前瞻性基于人群的研究中,我们进行了一项巢式病例对照研究,以检验以下假设:较高的高分子量激肽原(HK)或前激肽释放酶血浆水平与更高的 VTE 发生率相关。我们将 1993 年至 1995 年的酶联免疫吸附测定(ELISA)测量的 HK 和前激肽释放酶的基线水平与下肢( = 612)到 2015 年的 VTE 发生率(平均随访时间为 18 年)相关。我们没有发现证据表明 HK 或前激肽释放酶与新发 VTE 呈正相关。事实上,在大多数比例风险回归模型中,HK 与 VTE 呈显著负相关。例如,每标准偏差 HK 浓度更高的 VTE 风险比为 0.88(95%置信区间为 0.81,0.97),在调整了几个 VTE 风险因素后。我们的研究结果表明,这些因素的血浆水平并不能决定普通人群中 VTE 的风险。